Nurix Therapeutics's three largest insider shareholders as of September 29, 2026 are Gwenn Hansen (Chief Scientific Officer, 117.23K shares), Houte Hans Van (Chief Financial Officer, 40.17K shares), Julia P Gregory (Director, 10.75K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Gwenn Hansen | Chief Scientific Officer | 117,227 | 0 | 117,227 | 63.9% | 01 Sep, 2026 |
| 2 | Houte Hans Van | Chief Financial Officer | 40,166 | 0 | 40,166 | 21.9% | 04 Aug, 2026 |
| 3 | Julia P Gregory | Director | 10,750 | 0 | 10,750 | 5.9% | 17 Sep, 2025 |
| 4 | Christine Ring | Chief Legal Officer | 9,110 | 0 | 9,110 | 5.0% | 02 Sep, 2026 |
| 5 | Stefani Wolff | Evp And Coo | 6,113 | 0 | 6,113 | 3.3% | 02 May, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 02 Sep, 2026 | Christine Ring | Chief Legal Officer | Acquired M | 5,787 | $8.72 | $50.46K | 14,897 | Direct |
| 02 Sep, 2026 | Christine Ring | Chief Legal Officer | Disposed S | 5,387 | $25.69 | $138.42K | 9,510 | Direct |
| 02 Sep, 2026 | Christine Ring | Chief Legal Officer | Disposed S | 400 | $26.64 | $10.66K | 9,110 | Direct |
| 02 Sep, 2026 | Christine Ring | Chief Legal Officer | Disposed M | 5,787 | $0.00 | $0 | 117,037 | Direct |
| 01 Sep, 2026 | Gwenn Hansen | Chief Scientific Officer | Acquired M | 1,452 | $1.86 | $2.70K | 118,679 | Direct |
| 01 Sep, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed S | 1,452 | $25.47 | $36.98K | 117,227 | Direct |
| 01 Sep, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed M | 1,452 | $0.00 | $0 | 60,858 | Direct |
| 05 Aug, 2026 | Gwenn Hansen | Chief Scientific Officer | Acquired M | 4,356 | $1.86 | $8.10K | 121,583 | Direct |
| 04 Aug, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed S | 1,500 | $23.87 | $35.80K | 119,838 | Direct |
| 04 Aug, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed S | 2,611 | $24.64 | $64.34K | 117,227 | Direct |
| 05 Aug, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed S | 4,356 | $25.00 | $108.90K | 117,227 | Direct |
| 05 Aug, 2026 | Gwenn Hansen | Chief Scientific Officer | Disposed M | 4,356 | $0.00 | $0 | 62,310 | Direct |
| 04 Aug, 2026 | Houte Hans Van | Chief Financial Officer | Disposed S | 1,794 | $23.89 | $42.86K | 43,133 | Direct |
| 04 Aug, 2026 | Houte Hans Van | Chief Financial Officer | Disposed S | 2,967 | $24.65 | $73.13K | 40,166 | Direct |
| 03 Aug, 2026 | Christine Ring | Chief Legal Officer | Acquired M | 5,787 | $8.72 | $50.46K | 25,699 | Direct |
| 03 Aug, 2026 | Christine Ring | Chief Legal Officer | Disposed S | 16,589 | $23.05 | $382.36K | 9,110 | Direct |
| 03 Aug, 2026 | Christine Ring | Chief Legal Officer | Disposed M | 5,787 | $0.00 | $0 | 122,824 | Direct |
| 30 Jul, 2026 | Houte Hans Van | Chief Financial Officer | Acquired M | 3,750 | $0.00 | $0 | 41,342 | Direct |
| 30 Jul, 2026 | Gwenn Hansen | Chief Scientific Officer | Acquired M | 3,750 | $0.00 | $0 | 118,755 | Direct |
| 30 Jul, 2026 | Christine Ring | Chief Legal Officer | Acquired M | 3,750 | $0.00 | $0 | 17,329 | Direct |